Molecular and structural characterization of RNA binding proteins acting as potential disease targets in cancer and neurology

• Grant number: 20/02006-0
• Support type: Research Grants - Research Partnership for Technological Innovation - PITE
• Duration: November 01, 2020 - April 30, 2023
• Field of knowledge: Biological Sciences - Biochemistry - Chemistry of Macromolecules
• Cooperation agreement: Agilent
• Principal researcher: Katlin Brauer Massirer
• Grantee: Katlin Brauer Massirer
• Home Institution: Centro de Biologia Molecular e Engenharia Genética (CBMEG). Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil
• Company: Agilent Technologies Brasil Ltda (Agilent)
• City: Campinas
• Assoc. researchers: José Matheus Camargo Bonatto ; Opher Gileadi
• Associated scholarship(s): 20/16094-8 - Structural charaterization of RNA binding proteins and fragment-based screening by Liquid Chromatography and mass spectrometry, BP.PD

Abstract

With the aim of expanding the druggable proteome and lead to the discovery of new medicines, we work on the characterization of understudied human proteins, which show preliminary connection to disease. Within this aim, research has been expanded on the importance of protein related to RNA biology as antibody and drug targets, including the proteins 'per se' and their upstream modulators as kinases and methyltranferases. Thus, RNA binding proteins as well as kinase proteins constitute important biological targets for the advancement of biopharma. Those proteins can be targeted by small-molecule chemical probes, which are molecules defined as having high affinity and selectivity for a target and which can enter the cell to engage the target in vivo. Probes work as a complement to biological reagents for target validation and can be refined to become new drugs. In addition, biological targets can also lead to immunotherapy. In this project we aim to contribute for the characterization of the RNA binding protein BICC (Bicaudal C Homology 1) and UHMK (U2AF homology motif Serine/Threonine-Protein kinase) as potential drug targets related to cancer and neurological. We will characterize its interactors, target mRNAs and search for new chemical ligands. (AU)